ANA Investigates Updates in Autoimmune Encephalitis, part 2, therapeutics

Jul 26, 2022

Last month on the podcast, we talked about updates in the diagnosis of autoimmune encephalitis. This month we turn to advances in the treatment of autoimmune encephalitis. Treating these conditions has traditionally been practitioner-dependent, and currently no FDA-approved therapies exist. But that’s beginning to change. Series 3, Episode 9. Featuring:

• Guest: Dr. Maarten Titulaer, Erasmus MC University Medical Center
• Interviewer/Producer: Dr. Rohini Samudralwar, University of Pennsylvania
• Disclosures: Dr. Titulaer disclosed that his institution receives consulting funds form UCB, Viela Bio (Horizon), and CSL Behring, he is the co-investigator on the ExTinguish trial funded in part by Horizon, and a PI IVIG trial funded by CSL Behring.